ArticleFrontiers in oncology2026
Papillary thyroid carcinoma with brain and lung metastases: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Papillary thyroid carcinoma (PTC) usually has a favorable prognosis, the concurrent occurrence of brain and lung metastases is extremely rare, thus such cases have significant clinical reporting value. We report a case of a patient with multifocal PTC who presented with delayed multiple metastases. Case presentation: In January 2025, a 61-year-old female suddenly developed speech impairment and right limb weakness without an obvious cause. Upon reviewing her medical history, it was found that she had undergone a total thyroidectomy six years earlier because of multiple papillary thyroid carcinomas. Upon admission, relevant examinations were performed: cranial MRI revealed a solitary mass in the left frontal lobe, and a chest CT revealed multiple nodules in both lungs. The postoperative pathological examination of the brain lesion and bronchoscopic biopsy of the mediastinal lymph nodes revealed metastatic thyroid cancer (Pax-8, Tg, and TTF-1 positive). Diagnostic ¹³¹I whole-body scan after high-dose radioactive iodine treatment (180 mCi) revealed no significant radioactive isotope uptake by the lung metastases, indicating a radioactive iodine-resistant disease. Subsequently, three cycles of systemic chemotherapy (albumin-bound paclitaxel combined with carboplatin) were tried, but they were discontinued because of extreme toxicity. Treatment and results: The patient underwent surgical resection of brain metastases, and then switched to the multi-kinase inhibitor anlotinib due to poor chemotherapy tolerance. After approximately 10 weeks of anlotinib treatment, the first CT assessment showed a partial response, with the lung metastases shrinking and partially resolving. The most recent follow-up CT (in March 2026) confirmed that the remission was ongoing. Conclusion: This case indicates that PTC can result in uncommon, delayed, and numerous distant metastases even years after radical surgery. This highlights the importance of life-long surveillance, including chest and crinial imagings. The partial remission with anlotinib underscores its value as a therapeutic option in this setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.